Skip to Content Facebook Feature Image

'Megalopolis' flops, 'The Wild Robot' soars at box office

ENT

'Megalopolis' flops, 'The Wild Robot' soars at box office
ENT

ENT

'Megalopolis' flops, 'The Wild Robot' soars at box office

2024-09-30 01:15 Last Updated At:01:20

NEW YORK (AP) — Francis Ford Coppola’s decades-in-the-making, self-financed epic “Megalopolis” flopped with moviegoers, while the acclaimed DreamWorks Animation family film “The Wild Robot” soared to No. 1 at the weekend box office.

“The Wild Robot,” Chris Sanders’ adaptation of Peter Brown’s bestseller, outperformed expectations to launch with $35 million in ticket sales in U.S. and Canada theaters, according to studio estimates Sunday. “Wild Robot” was poised to do well after critics raved about the story of a shipwrecked robot who raises an orphan gosling. Audiences agreed, giving the film an A CinemaScore. “Wild Robot” is likely set up a long and lucrative run for the Universal Pictures release.

Paul Dergarabedian, senior media analyst for Comscore, predicts “The Wild Robot” “may take a page from the ‘Elemental' playbook by opening to respectable box office and then looking toward long-term playability.” Pixar's “Elemental," which like “The Wild Robot" wasn't a sequel, debuted with a modest $30 million but went on to gross nearly $500 million worldwide.

Family movies, led by the year's biggest hit in “Inside Out 2,” have particularly powered the box office this year. David A. Gross, a film consultant who publishes a newsletter for Franchise Entertainment, said the genre should reach $6 billion worldwide in 2024 — which, he noted, "is back to pre-pandemic levels.”

“Megalopolis,” Coppola’s vision of a Roman epic set in modern-day New York, was never expected to perform close to that level. But the film’s $4 million debut was still sobering for a movie that Coppola bankrolled himself for $120 million. Following its premiere at the Cannes Film Festival, critics have been mixed on Coppola’s first film in 13 years. Audiences gave in a D+ CinemaScore.

By any financial measure, “Megalopolis” was a mega-flop. But from the start, the 85-year-old Coppola maintained money wasn’t his concern. Coppola fashioned the film, which he first began developing in the late 1970s, as a grand personal statement about human possibility.

“Everyone’s so worried about money,” Coppola told The Associated Press in an interview ahead of the film’s release. “I say: Give me less money and give me more friends.”

Studios passed on “Megalopolis” after Cannes. Lionsgate ultimately stepped forward to distribute it, for a fee. Coppola also picked up the tab for most of its $15 million in marketing costs. The film, which stars Adam Driver, Nathalie Emmanuel and Aubrey Plaza, also played in about 200 IMAX locations, which accounted for $1.8 million of its ticket sales.

After three weeks atop the box office, Tim Burton’s “Beetlejuice Beetlejuice” slid to second place with $16 million in its fourth weekend of release. The Warner Bros. sequel to the 1988 “Beetlejuice,” starring Michael Keaton and Winona Ryder, has amassed $250 million domestically in a month of release.

Third place went to “Transformers One,” the Transformers prequel starring Chris Hemsworth and Brian Tyree Henry. After its lower-than expected debut last weekend, the Paramount release collected $9.3 million on its second weekend.

“Megalopolis” was even bested by the Indian Telugu-language action film “Devara: Part 1.” It grossed $5.1 million in its opening weekend, good enough for fourth place.

Also debuting in theaters was Jason Reitman’s “Saturday Night,” an affectionate dramatization of the sketch-comedy institution on the night it first aired in 1975. On the same weekend the NBC series began its 50th season, Reitman’s movie launched in five New York and Los Angeles theaters and collected $265,000, good for a strong $53,000 per-theater average. “Saturday Night” goes nationwide in two weeks.

Estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore. Final domestic figures will be released Monday.

1. “The Wild Robot,” $35 million.

2. “Beetlejuice Beetlejuice," $16 million.

3. “Transformers One," $9.3 million.

4. “Devara: Part 1," $5.1 million.

5. “Speak No Evil," $4.3 million.

6. “Megalopolis," $4 million.

7. “Deadpool & Wolverine," $2.7 million.

8. “My Old Ass," $2.2 million.

9. “Never Let Go," $2.2 million.

10. “The Substance," $1.8 million.

Aubrey Plaza, from left, Francis Ford Coppola, and Nathalie Emmanuel attend the premiere of "Megalopolis" on Monday, Sept. 23, 2024, at AMC Lincoln Square in New York. (Photo by Evan Agostini/Invision/AP)

Aubrey Plaza, from left, Francis Ford Coppola, and Nathalie Emmanuel attend the premiere of "Megalopolis" on Monday, Sept. 23, 2024, at AMC Lincoln Square in New York. (Photo by Evan Agostini/Invision/AP)

This image released by Universal Pictures shows Roz, voiced by Lupita N'yongo, left, and Brightbill, voiced by Kit Connor, in a scene from DreamWorks Animation's "Wild Robot." (DreamWorks Animation/Universal Pictures via AP)

This image released by Universal Pictures shows Roz, voiced by Lupita N'yongo, left, and Brightbill, voiced by Kit Connor, in a scene from DreamWorks Animation's "Wild Robot." (DreamWorks Animation/Universal Pictures via AP)

LILLE, France & PARIS--(BUSINESS WIRE)--Nov 28, 2024--

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127719655/en/

Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research Organization (CRO) with over 20 years of expertise in preclinical drug development.

This partnership combines the strengths of both organizations to offer an integrated, end-to-end approach for preclinical development. Together, Dev4All and Pharmaseed aim to deliver comprehensive and competitive solutions that accelerate drug development and address the complexities of today’s R&D landscape.

With over two decades of experience in CRO services and ten years advancing drug development candidates from TRL3 to TRL5, this close cooperation provides tailored preclinical support, cutting-edge laboratory capabilities, and strategic expertise, complementing clients’ R&D efforts worldwide.

Revital Rattenbach, Executive Chair of Dev4All, said: "I am thrilled about the new collaboration between Dev4All and Pharmaseed, which marks an exciting step forward in our shared commitment to innovation. This commercial cooperation empowers us to scale our capabilities, elevate our global impact, and deliver tailor-made solutions that meet our client's needs while maintaining the highest standards of scientific rigor."

Shmuel Landau, Co-CEO of Pharmaseed, said: "This collaboration with Dev4All is an excellent opportunity to expand our European presence and integrate our comprehensive preclinical solutions with DEV4ALL innovative R&D platform. Together, we are committed to deliver top-tier services, ensuring clients achieve their scientific and clinical milestones."

About Dev4All:
Dev4All, powered by 4P-Pharma, is an R&D booster designed to provide a wide range of preclinical solutions. With a decade-long foundation in preclinical research, Dev4All is committed to transforming innovative ideas into clinical-stage candidates through collaboration and scientific excellence.

Dev4All and Pharmaseed Join Forces in Commercial Cooperation (Graphic: Business Wire)

Dev4All and Pharmaseed Join Forces in Commercial Cooperation (Graphic: Business Wire)

Recommended Articles